Safety, tolerability and immunogenicity of MSP3-CRM-Vac4All/Alhydrogel in healthy adults

A total of 42 healthy male and female participants aged 18 to 55 years will be enrolled and randomized into one of three cohorts. Three dose levels of a novel malaria vaccine, MSP3-CRM-Vac4All/ Alhydrogel®, will be evaluated: 3 µg, 10 µg and 30 µg total MSP3-CRM197 conjugate protein (corresponding to 1, 3, 10 µg MSP3 protein) administered as a primary series of three intramuscular (IM) injections, given on day 1, day 28, and day 56.

NCT number: NCT05197751

Study type: Interventional
Enrollment: 42 participants
Primary purpose: Prevention
Allocation:Randomized
Interventional Model: Parallel assignment
Masking :Open label
Phase: Phase I

Clinical trial registration

Vaccines

Dec 2021 — May 2023

Mali